Literature DB >> 26290064

Topiramate augmentation in a patient with obsessive-compulsive disorder.

Michael Van Ameringen1, Beth Patterson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26290064      PMCID： PMC4543099          DOI： 10.1503/jpn.150100

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  20 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review.

Authors:  J S Abramowitz
Journal:  J Consult Clin Psychol       Date:  1997-02

3.  12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.

Authors:  Paul J Grant; Lisa A Joseph; Cristan A Farmer; David A Luckenbaugh; Lorraine C Lougee; Carlos A Zarate; Susan E Swedo
Journal:  Neuropsychopharmacology       Date:  2013-12-19       Impact factor: 7.853

Review 4.  Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence.

Authors:  David A Camfield; Jerome Sarris; Michael Berk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-02-23       Impact factor: 5.067

Review 5.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 6.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

7.  Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial.

Authors:  Arash Mowla; Abdol Mohammad Khajeian; Ali Sahraian; Abdol Hamid Chohedri; Faramarz Kashkoli
Journal:  CNS Spectr       Date:  2010-11       Impact factor: 3.790

Review 8.  Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.

Authors:  Naomi A Fineberg; Samar Reghunandanan; Angus Brown; Ilenia Pampaloni
Journal:  Aust N Z J Psychiatry       Date:  2012-11-02       Impact factor: 5.744

9.  Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.

Authors:  O Uzun
Journal:  J Psychopharmacol       Date:  2008-11-14       Impact factor: 4.153

Review 10.  Obsessive compulsive disorder and the glutamatergic system.

Authors:  Catherine Kariuki-Nyuthe; Baltazar Gomez-Mancilla; Dan J Stein
Journal:  Curr Opin Psychiatry       Date:  2014-01       Impact factor: 4.741
View more
  1 in total

1.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.